Nu Skin Glows, It's Smile Time For CRY, INO Making Big Moves, PCYC On Watch

(RTTNews) - Nu Skin Enterprises Inc. (NUS) is trading at a new high after it significantly boosted its revenue outlook for Q2-2013, reflecting the strong momentum of its business. The company is scheduled to release its second-quarter 2013 results on Aug. 1.

The European regulators have approved Pfizer Inc.'s (PFE) pneumococcal conjugate vaccine, Prevenar 13, for expanded use in adults aged 18 to 49 years for active immunization for the prevention of invasive disease caused by vaccine-type Streptococcus pneumonia.

Previously, the vaccine was approved in the European Union only for use in infants, young children and adolescents aged 6 weeks to 17 years, as well as adults 50 years of age and older.

PFE is up 0.25%, currently trading at $28.42.

CryoLife Inc. (CRY) announced Wednesday that it has received FDA approval for its new Sologrip minimally invasive laser fiber-optic delivery system. Last month, the company received CE Mark for HeRo Graft, a proprietary graft-based solution for end-stage renal disease hemodialysis patients with limited access options and central venous stenosis.

The company also secured conditional Investigational Device Exemption approval to begin clinical trials for PerClot in the U.S. last month. PerClot is intended for use in surgical procedures as an adjunctive hemostatic device when control of capillary, venular, and arteriolar bleeding by pressure, ligature, and other conventional means is ineffective or impractical.

PerClot has CE Mark designation and its international sales were up 34 percent in Q1-2013 compared to the first quarter of 2012.

CRY is up 0.31% at $6.52.

Pharmacyclics Inc. (PCYC) has submitted a New Drug Application to the FDA for its investigational oral drug - Ibrutinib, seeking approval in the indications of mantle cell lymphoma and chronic lymphocytic leukemia /small lymphocytic lymphoma.

Ibrutinib is being developed by Pharmacyclics in partnership with Janssen. The company has also requested priority review for Ibrutinib NDA.

PCYC is trading at a new high of $98.94, up 10.5%.

Inovio Pharmaceuticals Inc. (INO) is trading at a new high after it announced compelling results from two phase I trials of its PENNVAX-B preventive HIV DNA vaccine delivered with a DNA adjuvant and with or without its proprietary CELLECTRA electroporation delivery device.

INO is up 27%, trading at $1.50.